CUTANEOUS T-CELL LYMPHOMA

This study tests whether a treatment called photopheresis, which filters and treats a patient's blood with light, can help people with early-stage cutaneous T-cell lymphoma (a type of skin cancer). Currently used only for advanced disease, researchers want to see if using it earl…

This early-phase study tests a combination of two drugs, mogamulizumab and brentuximab vedotin, in people with a rare type of skin lymphoma (CTCL or MF) that has been treated before. The main goal is to find a safe dose and understand side effects. About 10 adults with advanced d…

This early-phase study tests whether combining bexarotene (a vitamin A-like drug) with ultra-low dose total skin electron beam radiotherapy is safe and effective for people with a common form of cutaneous T-cell lymphoma called mycosis fungoides. About 20 adults with stage IB or …

This study tests whether combining two drugs, pembrolizumab and mogamulizumab, can shrink or eliminate advanced cutaneous T-cell lymphoma that has come back or not responded to prior treatment. About 23 adults with stage IIB-IVB disease will receive the drugs in 6-week cycles for…

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refractory p…

This early-phase trial tests a new drug called ST-001 in people with T-cell non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to find the safest dose and to watch for side effects. About 46 participants will receive the drug through a…

This early-phase trial tests an experimental drug called ropeginterferon in 38 people with cutaneous T-cell lymphoma (a rare type of skin cancer) whose disease has not responded to at least two prior treatments. The main goals are to find the safest dose and see how many patients…

This study tests a gel called HyBryte, which is activated by visible light, to treat a rare type of skin lymphoma (CTCL). About 80 adults with early-stage disease will apply the gel to their skin lesions and then receive light treatment. The goal is to see if the gel can shrink o…

This study tests a cream called tofacitinib for people with early-stage cutaneous T-cell lymphoma (CTCL), a rare skin cancer. The goal is to see if the cream is safe and can control the disease. About 20 adults with stage IA, IB, or IIA CTCL will apply the cream and be monitored …

This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have come back or not responded to prior therapy. About 48 adults will receive the drug to see if it can shrink tumors and control the disease. The goal is to improv…

This study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…

This study is collecting information from 400 people with cutaneous T-cell lymphoma to see which systemic (body-wide) treatments doctors actually use and in what order. The goal is to understand real-world treatment patterns, not to test a new drug. Participants must be at least …

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research to better understand these skin conditions. Participants must be 18 or older and have a…

This study looks at the types of bacteria living on the skin of people with cutaneous T cell lymphoma and compares them to healthy people of similar age and sex. Researchers aim to understand how the skin microbiome differs in this rare cancer. The study involves 300 participants…